Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Leases (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Operating Leases over the past 3 years, most recently at $1.2 million for Q4 2025.

  • Quarterly results put Operating Leases at $1.2 million for Q4 2025, up 230.73% from a year ago — trailing twelve months through Dec 2025 was $1.2 million (up 230.73% YoY), and the annual figure for FY2025 was $1.2 million, up 230.73%.
  • Operating Leases for Q4 2025 was $1.2 million at Tonix Pharmaceuticals Holding, up from $266000.0 in the prior quarter.
  • Over the last five years, Operating Leases for TNXP hit a ceiling of $1.2 million in Q4 2025 and a floor of $266000.0 in Q3 2025.
  • Median Operating Leases over the past 3 years was $597500.0 (2023), compared with a mean of $638250.0.
  • Peak annual rise in Operating Leases hit 230.73% in 2025, while the deepest fall reached 61.43% in 2025.
  • Tonix Pharmaceuticals Holding's Operating Leases stood at $632000.0 in 2023, then tumbled by 43.35% to $358000.0 in 2024, then surged by 230.73% to $1.2 million in 2025.
  • The last three reported values for Operating Leases were $1.2 million (Q4 2025), $266000.0 (Q3 2025), and $297000.0 (Q2 2025) per Business Quant data.